本次股权转让交割手续完成后，公司仍持有中普生物48.99%的股权，中普生物将不再为公司控股子公 司，其财务数据不再纳入公司合并报表范围。 中牧实业股份有限公司关于放弃控股子公司 股权优先购买权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次交易情况概述 中牧实业股份有限公司（以下简称"中牧股份"或"公司"）于2025年11月13日、2025年12月1日分别召开 公司第九届董事会2025年第十三次临时会议、2025年第三次临时股东会，审议通过《关于放弃控股子公 司股权优先购买权的议案》，同意公司放弃认购中信农业科技股份有限公司持有的中普生物制药有限公 司（以下简称"中普生物"）4.04%的股权，由普莱柯生物工程股份有限公司（以下简称"普莱柯"）或其 他第三方摘牌受让股权。具体内容详见公司于2025年11月15日披露的《中牧实业股份有限公司关于放弃 控股子公司股权优先购买权的公告》（公告编号：临2025-036）和2025年12月2日披露的《中牧实业股 份有限公司2025年第三次临时股东会决议公告》（公告编号： ...

Core Viewpoint - The company emphasizes its strategic focus on the pet sector, aiming for rapid business development through innovation and investment partnerships [1] Group 1: Strategic Focus - The company is committed to expanding its own brand product market by enhancing product innovation, optimizing channels, and improving service quality [1] - The company is exploring investment collaborations to diversify its pet product offerings, supporting the rapid growth of its pet business segment [1] Group 2: Vaccine Development - The company has no plans to diversify into human vaccines, despite the similarities in immune mechanisms between animal and human vaccines, due to significant differences in regulatory approval, application scenarios, and usage requirements [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-050 普莱柯生物工程股份有限公司 关于认购中信农业所持中普生物股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易概况 普莱柯生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 2 日召 开第五届董事会第二十一次会议，审议通过拟认购中信农业科技股份有限公司 （以下简称"中信农业"）所持中普生物制药有限公司（以下简称"中普生物"） 股权的事项；具体详见公司于 2025 年 12 月 3 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于拟认购中信农业所持中普生物股权暨购买资产 的公告》（公告编号：2025-049）。 二、本次交易进展及对公司的影响 近日，公司在完成参与竞拍、确定成为产权交易受让方等相关法定程序后， 于 2025 年 12 月 10 日与中信农业签署《产权交易合同》，并于 2025 年 12 月 15 日取得上海联合产权交易所有限公司出具的《产权交易凭证（A1 类-挂牌类）》， 具体内容如下： ...

普莱柯公告，公司于2025年12月10日与中信农业签署《产权交易合同》，并于2025年12月15日取得上海 联合产权交易所有限公司出具的《产权交易凭证（A1类-挂牌类）》，以1751.43万元受让中普生物制药 有限公司4.04%股权。交易完成后，普莱柯将持有中普生物51.01%股权，中普生物将成为普莱柯控股子 公司。交易资金来源为公司自有资金，不影响现有主营业务正常开展，不会对公司财务状况及经营成果 产生重大影响。 ...

Core Insights - The report emphasizes the accelerated reduction of pig production capacity and highlights investment opportunities in raw milk and beef cattle sectors [2][15]. Livestock Farming - As of December 12, the average price for lean pigs in China is 11.03 CNY/kg, unchanged from the previous week but down 33.2% year-on-year. The industry continues to face significant supply pressure and losses due to short-term demand stagnation and regional epidemics [7][15]. - The number of breeding sows decreased by 1.1% month-on-month in October, indicating a more pronounced decline compared to September. The winter season is noted as a high-risk period for pig diseases, which may further impact production capacity [15]. - Recommended leading companies include Wens Foodstuffs Group and Muyuan Foods, with additional attention on Dekang Agriculture and New Hope Liuhe. Companies with potential for operational turnaround include Zhengbang Technology, while smaller firms like Tiankang Biological and Shennong Group are also suggested for consideration [15]. - For broiler chickens, the average price for live chickens and chicks is 3.65 CNY/jin and 3.54 CNY/chick, respectively, both showing a week-on-week increase of 1.4% [15]. Dairy Sector - The current price for fresh milk in major production areas is 3.02 CNY/kg, stable week-on-week but down 3.2% year-on-year. The industry is expected to continue reducing capacity due to long-term losses and financial pressures [16]. - The report anticipates a gradual balance in supply and demand as previous capacity reductions take effect, with a positive outlook for the raw milk cycle in 2026-2027 [16]. - Recommended companies in the dairy sector include Yurun Agriculture and Modern Farming [16]. Feed and Animal Health - The report notes a mixed performance in aquatic product prices, with a significant rebound in white shrimp prices due to previous disease outbreaks and delayed stocking [17]. - The aquaculture industry is expected to improve in 2025 compared to 2023-2024, although profitability is projected to remain lower than pre-2023 levels, necessitating upgrades in feed formulations and farming techniques [17]. - Leading feed companies are expected to enhance their market share domestically and expand internationally, leveraging their cost advantages [17]. - Key companies to watch in the animal health sector include Keqian Biological, Pulaike, Ruipu Biological, and Biological Shares, as they expand into pet healthcare [17]. Crop Sector - The domestic corn spot price is 2357 CNY/ton, remaining stable, while soybean meal prices have increased by 1.5% to 3159 CNY/ton [18]. - The report highlights the importance of monitoring weather conditions in South America and trade factors affecting soybean prices [18]. - Companies to focus on in the seed industry include Suqian Agricultural Development, Beidahuang, and Longping High-Tech [18]. Pet Food Industry - The global production layout of pet food companies is maturing, with limited impact from trade frictions on overseas operations. The domestic market shows high growth potential, driven by functional and health-oriented products [20]. - The industry is witnessing a trend towards consolidation, with leading companies like Guibao Pet and Zhongchong Shares showing strong brand performance [20]. - The long-term outlook remains positive for industry growth and the rise of domestic brands [20].

Investment Rating - The report maintains a positive outlook on leading agricultural companies, suggesting investment opportunities in the sector [5]. Core Insights - The agricultural sector has shown resilience, with the industry index outperforming the broader market by 0.4 percentage points during the week of December 8-12, 2025 [13]. - The report highlights significant growth in the pet food segment, with online sales increasing by 27.9% year-on-year during October and November 2025, driven by new consumer brands [34][36]. - The livestock industry is facing challenges, with a 5.5% decrease in the number of pigs marketed in November compared to the previous month, raising concerns about animal disease outbreaks [30]. Summary by Sections Industry Dynamics - The agricultural sector index increased by 0.3%, outperforming the market [13]. - Key stocks such as Zhengbang Technology, Biological Shares, and Luoniushan saw significant gains of 19%, 17%, and 14% respectively [18]. Livestock Industry - In November, the number of pigs marketed decreased by 5.5% month-on-month, with a year-on-year increase of 16.7% [30]. - Prices for live pigs increased by 2.1% week-on-week, while the average weight of marketed pigs decreased by 0.2% [30]. - The utilization rate of fattening barns in 17 provinces dropped by 6.5 percentage points [30]. Poultry Industry - Prices for chicken chicks and broilers increased by 1.4% and 0.8% respectively, amid ongoing global avian influenza outbreaks [37][38]. - The price of chicken products rose by 0.6%, driven by supply constraints and increased export orders [37]. Pet Food Industry - Online sales of pet food reached 8.45 billion yuan, with significant growth from brands like Maifudi and Fresh Lang, which saw increases of 36% and 112.6% respectively [34]. - Chewy reported a 30.9% increase in EBITDA, with active customer numbers growing by 4.9% [35]. Feed Industry - Feed raw material prices showed mixed trends, with soybean meal prices increasing by 1.5% while corn prices slightly decreased [41]. - The price of South American white shrimp increased by 4.3% week-on-week [41]. Animal Health - The veterinary drug price index decreased by 0.2%, with a year-on-year increase of 2.4% [43]. - Merck's imported pet antibiotics were launched on JD Health, marking a significant development in the pet healthcare sector [43].

Group 1: Pig Farming Industry - The current sales of fat pigs and piglets are in a loss state, indicating that the industry is in a precondition for capacity reduction [1] - Continuous losses in farming, combined with the "anti-involution" policy, are expected to accelerate capacity reduction in the industry, creating a left-side layout window for the pig farming sector [1] - By 2026, it is anticipated that there will be an upward turning point in pig prices, as competition in the industry intensifies and companies focus on comprehensive competitive capabilities rather than just cost competition [1] Group 2: Dairy Industry - In 2025, raw milk prices are expected to continue to bottom out, with industry losses driving a reduction in dairy cow inventory [2] - As the effects of previous capacity reduction become evident, the supply and demand for raw milk are gradually balancing, leading to a stabilization and rebound in spot milk prices in the second half of 2025 [2] - The beef supply is entering a contraction phase, with expectations for beef prices to continue to rise in 2026, increasing performance elasticity [2] Group 3: Feed Industry - The water feed sector is expected to maintain stable aquaculture volumes in 2026, with a trend of technical upgrades and structural adjustments continuing [3] - Domestic feed demand for livestock and poultry is projected to decline from high levels, while structural changes in the overseas feed industry present opportunities for Chinese feed companies to expand internationally [3] Group 4: Animal Health Industry - The animal health industry faces intensified competition, with product prices under pressure as the farming sector transitions from profit to loss [4] - Revenue and profitability in the industry may face significant challenges, prompting companies to accelerate business transformation and explore opportunities in the pet business [4] Group 5: Pet Food Industry - The industry is beginning to show a trend towards concentration, with leading companies like Guibao Pet and Zhongchong Co. performing well [5] - In the medium to long term, there is optimism for industry growth and the rise of domestic brands, with companies leveraging global production layouts to mitigate trade friction impacts [5] Group 6: Agricultural Planting Industry - Corn prices are expected to bottom out and rebound in 2025, with a strong possibility of fluctuations in 2026 [6] - The corn seed market is currently in a state of oversupply, undergoing a destocking phase, and may see improved conditions as inventory levels decrease [6]

Investment Recommendations - The pig farming sector is currently facing losses for both fat and piglet sales, indicating conditions for capacity reduction. The industry is expected to accelerate capacity reduction, presenting a left-side layout opportunity for the pig farming sector. A price turning point is anticipated in mid-2026 [16][20][34] - Major pig farming companies recommended include Wens Foodstuffs Group and Muyuan Foods, with attention to Dekang Agriculture and New Hope. Companies with potential for operational turnaround include Zhengbang Technology, while smaller farming enterprises to watch include Tiankang Biological, Shennong Group, and Tangrenshen [16][34] Pig Industry Analysis - In 2025, the pig price fell below the cost line, leading to overall industry losses. By November, the average loss per self-breeding pig was 122 CNY per head, with an estimated annual profit of 30-80 CNY per head [20][23] - The industry is experiencing a significant reduction in breeding sow inventory, with a decrease to 39.9 million heads by October 2025, down 1.1% month-on-month and 2.1% year-on-year [28][36] Dairy Industry Analysis - The raw milk price continued to decline in 2025, leading to a reduction in dairy cow inventory. As the supply-demand balance improves, raw milk prices are expected to rise in 2026-2027 [16][18] - The beef supply is also entering a contraction phase, with expectations for beef prices to rise in 2026, enhancing the performance elasticity of livestock companies [16][18] Feed Industry Analysis - The feed sector is expected to see stable water aquaculture production in 2026, while demand for livestock feed is projected to decline due to reduced breeding capacity. Domestic feed leaders are positioned to benefit from overseas expansion opportunities [17][18] - The global feed industry is undergoing structural changes, providing opportunities for Chinese feed companies to expand internationally [17] Animal Health Industry Analysis - The animal health sector faces intensified competition, with traditional vaccine product margins declining. Companies are shifting towards multi-business models, including pet health products, to open new growth avenues [17][18] Pet Food Industry Analysis - The pet food market is showing signs of consolidation, with leading companies like Guai Bao Pet and Zhongchong Co. performing well. The long-term growth logic for the industry remains strong, supported by the rise of domestic brands [17][18] - Companies are also expanding their global production capabilities to mitigate trade friction impacts [17] Crop Industry Analysis - Corn prices are expected to rebound in 2025, with a potential strong performance in 2026. The seed industry is currently in a phase of inventory reduction, with opportunities arising from transgenic innovations and industry consolidation [18][19]

Core Insights - The animal health sector experienced a decline of 0.31% on December 10, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3900.5, down 0.23%, while the Shenzhen Component Index rose by 0.29% to 13316.42 [1] Stock Performance - The following stocks in the animal health sector showed varied performance: - **Biological Shares (600201)**: Closed at 14.53, up 1.18% with a trading volume of 395,300 shares and a turnover of 560 million yuan [1] - **Ruipu Biological (300119)**: Closed at 19.24, up 0.79% with a trading volume of 26,900 shares and a turnover of 51.56 million yuan [1] - **Xianfeng Holdings (002141)**: Closed at 3.82, up 0.53% with a trading volume of 177,700 shares and a turnover of 67.70 million yuan [1] - **Qudongli (920275)**: Closed at 8.71, up 0.23% with a trading volume of 9,815 shares and a turnover of 8.47 million yuan [1] - **Jinhe Biological (002688)**: Closed at 6.05, down 0.17% with a trading volume of 67,700 shares and a turnover of 40.90 million yuan [1] - **Hui Sheng Biological (300871)**: Closed at 19.24, down 0.52% with a trading volume of 23,700 shares and a turnover of 45.48 million yuan [1] - **Dayu Biological (920970)**: Closed at 7.70, down 0.65% with a trading volume of 11,700 shares and a turnover of 892,880 yuan [1] - **KQ Biological (688526)**: Closed at 15.36, down 0.65% with a trading volume of 17,600 shares and a turnover of 26.94 million yuan [1] - **Placo (603566)**: Closed at 12.95, down 0.69% with a trading volume of 27,200 shares and a turnover of 35.32 million yuan [1] - **Shenlian Biological (688098)**: Closed at 8.96, down 1.10% with a trading volume of 31,800 shares and a turnover of 28.66 million yuan [1] Capital Flow - On the same day, the animal health sector saw a net outflow of 13.98 million yuan from institutional investors and 18.34 million yuan from retail investors, while individual investors contributed a net inflow of 32.32 million yuan [3]

Core Viewpoint - The company, Pulaike (603566.SH), emphasizes its research and development capabilities in the veterinary medicine sector, despite concerns about its lag in vaccine development for major diseases like African swine fever compared to competitors. Group 1: R&D Infrastructure - The company has established multiple national and provincial-level innovation platforms, including the National Engineering Research Center for Veterinary Drugs and the National Key Laboratory for Animal Infectious Disease Diagnosis and Vaccine Development [1] - It has built a biosafety level 3 laboratory that is operational and has received approval for activities involving certain pathogenic microorganisms [1] Group 2: Technological Capabilities - The company has developed a comprehensive set of technical platforms over the years, including reverse genetics, prokaryotic and eukaryotic expression technologies, multivalent vaccine technology, high-density fermentation technology, and antigen concentration and purification technology [1] - These platforms enable the company to develop a series of genetically engineered vaccines [1] Group 3: Innovation and Achievements - The company has produced several innovative products that fill gaps in both international and domestic markets, including various inactivated vaccines for poultry and swine [1] - As of now, the company has obtained 81 national new veterinary drug registration certificates, filed over 600 invention patent applications, and received 340 invention patent grants, along with three second-class National Science and Technology Progress Awards [1]